Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in PIQ?
Proteomics International Laboratories Ltd: THE INVESTMENT CASE
INVESTMENT OVERVIEW

Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions

Richard Lipscombe talked revenue generation and growth path with investors.
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: PIQ The Big Picture
Richard Lipscombe, MD, Proteomics International Laboratories

Proteomics International Laboratories (ASX:PIQ) managing director, Richard Lipscombe, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April and Sydney on Wednesday, 12th April.

Proteomics is a revenue generating company holding the unique position as having the world's first diagnostic test at a commercialisation stage.

The company has proven technology with patents granted, with an Asian focus and global reach.

ACCESS THE FULL PRESENTATION HERE

View full PIQ profile View Profile

Proteomics International Laboratories Ltd Timeline

Related Articles

3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston
researcher filling a vial
May 29 2018
ImmuPharma chairman Tim McCarthy said: "We continue to believe Lupuzor has the potential to bring a much needed treatment to Lupus sufferers around the world"
bacteria
June 27 2018
Ridinilazole is a possible treatment for C. Difficile and Summit hopes to kick off a phase III trial in the first quarter of 2019

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use